B

BMC Medical Co Ltd
SZSE:301367

Watchlist Manager
BMC Medical Co Ltd
SZSE:301367
Watchlist
Price: 68.07 CNY -3.86% Market Closed
Market Cap: 6.1B CNY
Have any thoughts about
BMC Medical Co Ltd?
Write Note

BMC Medical Co Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

BMC Medical Co Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
B
BMC Medical Co Ltd
SZSE:301367
Cash & Cash Equivalents
ÂĄ668.7m
CAGR 3-Years
45%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Cash & Cash Equivalents
ÂĄ1.3B
CAGR 3-Years
120%
CAGR 5-Years
70%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Cash & Cash Equivalents
ÂĄ6.5B
CAGR 3-Years
35%
CAGR 5-Years
57%
CAGR 10-Years
36%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Cash & Cash Equivalents
ÂĄ20.5B
CAGR 3-Years
10%
CAGR 5-Years
11%
CAGR 10-Years
N/A
J
Jafron Biomedical Co Ltd
SZSE:300529
Cash & Cash Equivalents
ÂĄ1.7B
CAGR 3-Years
-11%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Cash & Cash Equivalents
ÂĄ7.5B
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

BMC Medical Co Ltd
Glance View

Market Cap
6.1B CNY
Industry
Health Care

BMC Medical Co. Ltd. principally engages in the research, development, production, and sale of medical equipment and consumable products in the field of respiratory health. The company is headquartered in Beijing, Beijing and currently employs 843 full-time employees. The company went IPO on 2022-11-01. The firm's products mainly include non-invasive home ventilators, ventilation masks, sleep monitors and high-flow humidified oxygen therapy devices. The firm also provides respiratory health chronic disease management services. The firm focuses on the treatment of patients with sleep apnea-hypopnea syndrome (SAHS), mainly obstructive sleep apnea syndrome (OSA), as well as patients with respiratory insufficiency, mainly chronic obstructive pulmonary disease (COPD), providing a full-cycle and multi-scenario overall solution for treatment services.

Intrinsic Value
63.17 CNY
Overvaluation 7%
Intrinsic Value
Price
B

See Also

What is BMC Medical Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
668.7m CNY

Based on the financial report for Dec 31, 2023, BMC Medical Co Ltd's Cash & Cash Equivalents amounts to 668.7m CNY.

What is BMC Medical Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 3Y
45%

Over the last year, the Cash & Cash Equivalents growth was 88%. The average annual Cash & Cash Equivalents growth rates for BMC Medical Co Ltd have been 45% over the past three years .

Back to Top